A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
February 27, 2014DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
February 18, 2014DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
February 12, 2014DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)
January 07, 2014Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR® Pain Patch